Shares of Inspire Medical Systems, Inc. (NYSE:INSP – Get Free Report) have been given a consensus rating of “Hold” by the nineteen ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and five have issued a buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $104.2353.
Several equities research analysts have weighed in on INSP shares. Stifel Nicolaus dropped their target price on Inspire Medical Systems from $95.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, March 5th. JPMorgan Chase & Co. upped their price target on shares of Inspire Medical Systems from $82.00 to $118.00 and gave the stock a “neutral” rating in a research report on Tuesday, December 16th. Jefferies Financial Group dropped their price objective on shares of Inspire Medical Systems from $81.00 to $66.00 and set a “hold” rating on the stock in a report on Thursday, February 12th. Morgan Stanley set a $60.00 price objective on shares of Inspire Medical Systems in a research report on Wednesday, February 18th. Finally, Robert W. Baird set a $74.00 target price on shares of Inspire Medical Systems and gave the company a “neutral” rating in a research note on Thursday, February 12th.
Get Our Latest Report on Inspire Medical Systems
Institutional Trading of Inspire Medical Systems
Inspire Medical Systems Trading Up 0.7%
NYSE:INSP opened at $58.64 on Friday. The firm has a market capitalization of $1.68 billion, a PE ratio of 11.77, a price-to-earnings-growth ratio of 2.90 and a beta of 0.74. The stock has a 50 day moving average of $73.86 and a 200-day moving average of $86.01. Inspire Medical Systems has a 52 week low of $53.11 and a 52 week high of $172.95.
Inspire Medical Systems (NYSE:INSP – Get Free Report) last announced its quarterly earnings results on Wednesday, February 11th. The company reported $1.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.96. The business had revenue of $269.08 million for the quarter, compared to analysts’ expectations of $264.02 million. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The business’s quarterly revenue was up 12.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.15 EPS. As a group, analysts predict that Inspire Medical Systems will post 2.16 EPS for the current fiscal year.
About Inspire Medical Systems
Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.
The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.
Further Reading
- Five stocks we like better than Inspire Medical Systems
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Silver paying 20% dividend. Plus 68% share gains
- Unlocked: Elon Musk’s Next Big IPO
- A personal warning from Martin Weiss (Please read)
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
